Vaccibody As Stock Profit Margin
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
Vaccibody As fundamentals help investors to digest information that contributes to Vaccibody's financial success or failures. It also enables traders to predict the movement of Vaccibody Stock. The fundamental analysis module provides a way to measure Vaccibody's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaccibody stock.
Vaccibody |
Vaccibody As Company Profit Margin Analysis
Vaccibody's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Vaccibody As has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all Norway stocks is 100.0% lower than that of the firm.
Vaccibody Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaccibody's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaccibody could also be used in its relative valuation, which is a method of valuing Vaccibody by comparing valuation metrics of similar companies.Vaccibody is currently under evaluation in profit margin category among its peers.
Vaccibody Fundamentals
| Return On Equity | -0.23 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (77.18) % | |||
| Current Valuation | 32.03 M | |||
| Shares Outstanding | 38.55 M | |||
| Shares Owned By Insiders | 3.45 % | |||
| Shares Owned By Institutions | 49.84 % | |||
| Number Of Shares Shorted | 159.22 K | |||
| Price To Earning | 12.63 X | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 2.31 X | |||
| Revenue | 44.7 M | |||
| Gross Profit | 44.7 M | |||
| EBITDA | 869 K | |||
| Net Income | 5.32 M | |||
| Cash And Equivalents | 192.33 M | |||
| Cash Per Share | 5.17 X | |||
| Total Debt | 8.77 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 18.60 X | |||
| Book Value Per Share | 5.64 X | |||
| Cash Flow From Operations | (14.43 M) | |||
| Short Ratio | 0.08 X | |||
| Earnings Per Share | (1.59) X | |||
| Target Price | 9.31 | |||
| Number Of Employees | 33 | |||
| Beta | -0.39 | |||
| Market Capitalization | 192.73 M | |||
| Total Asset | 270.2 M | |||
| Retained Earnings | (103.24 M) | |||
| Working Capital | 200.8 M | |||
| Z Score | 13.71 | |||
| Net Asset | 270.2 M |
About Vaccibody Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaccibody As's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaccibody using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaccibody As based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |